NRXP News and Press, NRX Pharmaceuticals Inc.

NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...

NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter PR Newswire The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging stan...

NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression PR Newswire ...

2024-05-14 20:11:06 ET NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Results Conference Call May 14, 2024 04:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder, Chairman an...

2024-05-14 16:23:20 ET More on NRx Pharmaceuticals NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript NRx Pharmaceuticals climbs on positive results from its bipolar depression treatment trial NRx Pharmaceuticals regains compliance with Nasdaq minimum ...

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire 2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity ...

2024-05-13 17:35:36 ET Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. ( OXLC ) Capital Southwest Corporation ( CSWC ) Seadrill Limited ( SDRL ) Nu Holdings Ltd. ( NU ) Canoo ( GOEV ) Read the full articl...

2024-05-08 09:07:02 ET Michigan, United States, April 29th, 2024, FinanceWire NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, spe...